Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Dammes, Niels; Peer, Dan

doi:10.7150/thno.37443

Cited by 92 publications

(102 citation statements)

References 143 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…nanobodies) and peptides. Dammes and Peer summarize the applications of monoclonal antibodies in molecular imaging of cancer, autoimmune disorders and cardiovascular diseases 26 . In addition, the potential of using monoclonal antibody-based molecular imaging strategies in theranostics and precision medicine is highlighted.…”

mentioning

confidence: 99%

The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

et al. 2020

View full text Add to dashboard Cite

Following its discovery more than 30 years ago, the enhanced permeability and retention (EPR) effect has become the guiding principle for cancer nanomedicine development. Over the years, the tumor-targeted drug delivery field has made significant progress, as evidenced by the approval of several nanomedicinal anticancer drugs. Recently, however, the existence and the extent of the EPR effect - particularly in patients - have become the focus of intense debate. This is partially due to the disbalance between the huge number of preclinical cancer nanomedicine papers and relatively small number of cancer nanomedicine drug products reaching the market. To move the field forward, we have to improve our understanding of the EPR effect, of its cancer type-specific pathophysiology, of nanomedicine interactions with the heterogeneous tumor microenvironment, of nanomedicine behavior in the body, and of translational aspects that specifically complicate nanomedicinal drug development. In this virtual special issue, 24 research articles and reviews discussing different aspects of the EPR effect and cancer nanomedicine are collected, together providing a comprehensive and complete overview of the current state-of-the-art and future directions in tumor-targeted drug delivery.

show abstract

mentioning

confidence: 99%

The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Owing to the dimension of investment involved, and the need for a more efficient process of drug development, there is renewed interest in utilizing molecular imaging for preclinical and clinical development of drugs, including ADCs. Molecular imaging allows the development of imaging probes that can identify target expression or can image drug distribution and confirm in vivo target delivery and normal tissue distribution and pharmacokinetics in real time [ 168 ]. Molecular imaging has been successfully used in ADC preclinical studies and in clinical trials in order to determine tumor target expression, drug stability and delivery to the tumor, and interlesional target heterogeneity.…”

Section: Role Of Molecular Imaging In the Clinical Development Of mentioning

confidence: 99%

Antibody–Drug Conjugates for Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

show abstract

“…Antibodies are a popular choice as targeting moieties due to their specificity, high affinity, well-defined structure, and long in vivo circulation time [ 66 ]. Multiple studies have used antibody–siRNA conjugates (ARCs) with different methods of linking the antibody to the siRNA molecule.…”

Section: Delivery Of Rna Therapeuticsmentioning

confidence: 99%

Paving the Road for RNA Therapeutics

Dammes

Peer

2020

Trends in Pharmacological Sciences

Self Cite

160

152

View full text Add to dashboard Cite

Therapeutic RNA molecules possess high potential for treating medical conditions if they can successfully reach the target cell upon administration. However, unmodified RNA molecules are rapidly degraded and cleared from the circulation. In addition, their large size and negative charge complicates their passing through the cell membrane. The difficulty of RNA therapy, therefore, lies in the efficient intracellular delivery of intact RNA molecules to the tissue of interest without inducing adverse effects. Here, we outline the recent developments in therapeutic RNA delivery and discuss the wide potential in manipulating the function of cells with RNAs. The focus is not only on the variety of delivery strategies but also on the versatile nature of RNA and its wide applicability. This wide applicability is especially interesting when considering the modular nature of nucleic acids. An optimal delivery vehicle, therefore, can facilitate numerous clinical applications of RNA.

show abstract

Monoclonal antibody-based molecular imaging strategies and theranostic opportunities

Cited by 92 publications

References 143 publications

The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

Antibody–Drug Conjugates for Cancer Therapy

Paving the Road for RNA Therapeutics

Contact Info

Product

Resources

About